At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 500 enrolled
Drug / intervention
Docetaxel/Cisplatin control +3 moredrug
Likely dose
Docetaxel/Cisplatin control 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients
In Brief
A Phase 3 clinical trial evaluating Docetaxel/Cisplatin control, Docetaxel, and 2 other interventions for Non-small-cell Lung Cancer. Completed, enrolled 500 participants across 47 sites.
Detailed Summary
Randomized Study of Customized Adjuvant Chemotherapy based on BRCA1 mRNA Levels in Completely Resected stages II-IIIA Non-Small-Cell Lung Cancer Patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small-cell Lung Cancer
CountriesSpain
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartJun 2007
Primary CompletionJun 2015
Study CompletionJul 2015
TodayJul 2026
First PostedMay 25, 2007
Enrollment StartJun 1, 2007
Primary CompletionJun 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 yearsPosted 19.1 years ago
Interventions
Docetaxel/Cisplatin controldrug
Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
Docetaxeldrug
Docetaxel 75 mg/m2 day 1, 4 cycles
Gemcitabine/Cisplatindrug
Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
Docetaxel/Cisplatindrug
Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles